Main Article Content

Authors

Background: There is limited information on population-based cancer survival data in Latin America.

Objetive: To obtain estimates of survival for some cancers recognized as a public health priority in Colombia using data from the Cancer Registry of Cali for 1995-2004.

Methods: All cancer cases for residents of Cali were included for the following sites: breast (3,984), cervix uteri (2,469), prostate (3,999), stomach (3,442) and lung (2,170).  Five-year relative survival estimates were calculated using the approach described by Estève.

Results: Five-year relative survival was 79% in patients with prostate cancer and 68% and 60% in women with breast or cervix uteri cancer, respectively. The cure fraction was 6% in subjects with lung cancer and 15% in those with stomach cancer. The probability of dying from breast or prostate cancer in people in the lower socio-economic strata (SES) was 1.8 and  2.6  times greater,  respectively,  when compared to  upper SES, p <0.001. Excess mortality associated with cancer was independent of age in prostate or breast cancer.  After adjusting for age, sex and SES, the risk of dying from breast, cervix uteri, prostate and lung cancer during the 2000-2004 period decreased 19%, 13%, 48% and 16%, respectively, when compared with the period of 1995-1999. There was no change in the prognosis for patients with stomach cancer.

Conclusions: Survival for some kinds of cancer improved through the 1995-2004 period, however health care programs for cancer patients in Cali are inequitable. People from lower SES are the most vulnerable and the least likely to survive.

 

Gloeckler RL, Hankey B, Harras A, Devesa S. Cancer incidence, mortality, and patient survival in the United States. In: Schottenfeld D, Fraumeni FJ. Cancer epidemiology and prevention, 2nd ed., vol. 2. New York: Oxford University Press, 1996: 168–91.

Berrino F, Gatta G, Sant M, Capocaccia R. The EUROCARE study of survival of cancer patients in Europe: aims, current status, strengths and weaknesses. Eur J Cancer. 2001; 37: 673–7. DOI: https://doi.org/10.1016/S0959-8049(01)00008-9

Sant M, Capocaccia R, Coleman MP, Berrino F, Gatta G, Micheli A, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer. 2001; 37: 1659–67. DOI: https://doi.org/10.1016/S0959-8049(01)00206-4

Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007; 8: 784–96. DOI: https://doi.org/10.1016/S1470-2045(07)70246-2

Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD) Lancet Oncol. 2008; 9: 730–56. DOI: https://doi.org/10.1016/S1470-2045(08)70179-7

Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010; 11: 165–73. DOI: https://doi.org/10.1016/S1470-2045(09)70335-3

Coleman MP. Cancer survival in the developing world. Lancet Oncol. 2010; 11: 110–1. DOI: https://doi.org/10.1016/S1470-2045(09)70371-7

Berrino F, Estève J, Coleman MP. Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ. 1995; (132): 1–14.

Coebergh JW, Sant M, Berrino F, Verdecchia A. Survival of adult cancer patients in Europe diagnosed from 1978-1989 the Eurocare II study. Europ J Cancer. 1998; 34: 2137–278.

Bravo LE, Collazos T, Collazos P, García LS, Correa P. Trends of Cancer Incidence and Mortality in Cali, Colombia. 50 years experience. Colomb Med (Cali) 2012; 43(4): 246-25. DOI: https://doi.org/10.25100/cm.v43i4.1266

Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012; 61: 1079–92. DOI: https://doi.org/10.1016/j.eururo.2012.02.054

Curado M, Edwards B, Shin H, Storm H, Ferlay J, Heanue M, et al. Cancer Incidence in Five Continents.Vol. IX. Lyon: IARC Press; 2007.

Doll R, Muir C, Waterhouse J. Cancer Incidence in Five Continents.Vol. II. New York: Springer-Verlag Berlin - Heidelberg; 1970. DOI: https://doi.org/10.1007/978-3-642-85851-2

Muir C, Waterhouse J, Mack T, Powell J, Whelan S. Cancer Incidence in Five Continents.Vol. V. Lyon: IARC Press; 1987. DOI: https://doi.org/10.1007/978-1-4684-1288-8_1

Parkin D, Muir C, Whelan S, Gao Y, Ferlay J, Powell J. Cancer Incidence in Five Continents.Vol. VI. Lyon: IARC Press; 1992.

Parkin D, Whelan S, Ferlay J, Raymond L, Young J. Cancer Incidence in Five Continents.Vol. VII. Lyon: IARC Press; 1997.

Parkin D, Whelan S, Ferlay J, Teppo L, Thomas D. Cancer Incidence in Five Continents.Vol. VIIIed. Lyon: IARC Press; 2002.

Waterhouse J, Muir C, Shanmugaratnam K, Powell J. Cancer Incidence in Five Continents.Vol. IVed., vol. 42. Lyon: IARC Press; 1982.

Waterhouse J, Muir C, Correa P, Powell J. Cancer Incidence in Five Continents. III .ed. vol. 15. IARC Press; 1984.

EZU Enterprise. Geografic business intelligence solutions (Geobis International) 9.0.

Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. National Cancer Institute Monograph. 1961; 6: 101–21.

Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics. 1982; 38: 933–42. DOI: https://doi.org/10.2307/2529873

Surveillance Research Program NCI . SEER*Stat software, ed.Version. MD: National Cancer Institute; 2012.

Estève J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of net survival: elements for further discussion. Stat Med. 1990; 9: 529–38. DOI: https://doi.org/10.1002/sim.4780090506

Gamel JW, Weller EA, Wesley MN, Feuer EJ. Parametric cure models of relative and cause-specific survival for grouped survival times. Comput Methods Programs Biomed. 2000; 61: 99–110. DOI: https://doi.org/10.1016/S0169-2607(99)00022-X

CanSurv Statistical Methodology and Applications Branch.Data Modeling Branch.National Cancer Institute.ed . Version 1.1. Bethesda: MD; 2012.

Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012; 104: 125–132. DOI: https://doi.org/10.1093/jnci/djr500

Aristizabal N, Cuello C, Correa P, Collazos T, Haenszel W. The impact of vaginal cytology on cervical cancer risks in Cali, Colombia. Int J Cancer. 1984; 34: 5–9. DOI: https://doi.org/10.1002/ijc.2910340103

Anderson BO, Yip CH, Ramsey SD, Bengoa R, Braun S, Fitch M, et al. Breast cancer in limited-resource countries: health care systems and public policy. Breast J. 2006; 12(1): S54–S69. DOI: https://doi.org/10.1111/j.1075-122X.2006.00203.x

Charry LC, Carrasquilla G, Roca S. Equity regarding early breast cancer screening according to health insurance status in Colombia. Rev Salud Publica. 2008; 10: 571–82. DOI: https://doi.org/10.1590/S0124-00642008000400007

Tsai TC. Second chance for health reform in Colombia. Lancet. 2010; 375: 109–10. DOI: https://doi.org/10.1016/S0140-6736(10)60033-5

Yamin AE. Colombia’s health reform: false debates, real imperatives. Lancet. 2010; 375: 803. DOI: https://doi.org/10.1016/S0140-6736(10)60340-6

Bravo, L. E., García, L. S., & Collazos, P. A. (2014). Cancer survival in Cali, Colombia: A population-based study, 1995-2004. Colombia Medica, 45(3), 110–116. https://doi.org/10.25100/cm.v45i3.1525

Downloads

Download data is not yet available.
1 2 3 4 > >> 

Similar Articles

You may also start an advanced similarity search for this article.